["The lower LDL cholesterol levels, the better" still valid. Negative/neutral conclusions of three studies on statins do not change the clinical practice].
Olsson
Anders G
AG
Institutionen för medicin och hälsa, Hälsouniversitetet, Linköping. andol@imv.liu.se
Nilsson
Peter M
PM
D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001384:Azetidines / Q000009:adverse effects / Q000627:therapeutic use*; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D019317:Evidence-Based Medicine; D000069438:Ezetimibe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy; D006938:Hyperlipoproteinemia Type II / Q000150:complications / Q000188:drug therapy; D017063:Outcome Assessment, Health Care; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use*; D019821:Simvastatin / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D001384:Azetidines; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011804:Quinolines; C483909:torcetrapib; D019821:Simvastatin; D000069438:Ezetimibe